Top 5 AI-Powered Biotech Stocks to Buy Right Now

3. Caris Life Sciences, Inc. (NASDAQ:CAI)

Number of Hedge Fund Holders: 44

Caris Life Sciences, Inc. (NASDAQ:CAI) is among the best biotech stocks. 

TheFly reported on April 10 that Piper Sandler began coverage of CAI with a Neutral rating and a $21 price target. The firm highlighted the company’s combination of strong scientific capabilities and relatively stable financial profile compared to many peers in the space. It projected revenue growth of around 20% over the next few years but indicated that further acceleration in therapy selection services, potentially driven by Salesforce expansion or new product offerings, would be needed before adopting a more positive stance on the stock.

In a significant operational development, on April 1, Caris Life Sciences, Inc. (NASDAQ:CAI) introduced Caris ChromoSeq, a new genomic testing platform combining whole genome and whole transcriptome sequencing to evaluate myeloid cancers. The assay is designed for conditions such as acute myeloid leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms, as well as cases with persistent unexplained cytopenia.

It enables comprehensive detection of mutations, structural changes, and chromosomal abnormalities through a single test, reducing the need for multiple diagnostic procedures. The platform delivers in-depth genomic data and integrates findings into a unified report, supporting faster and more informed clinical decisions. Results are expected within approximately seven days, improving efficiency in patient care.

Caris Life Sciences, Inc. (NASDAQ:CAI) is an AI-driven precision medicine company that uses large-scale clinico-genomic data and molecular profiling to guide cancer diagnosis and treatment. Its platforms apply machine learning to predict therapy response and improve personalized oncology outcomes.